MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

IDXX · NASDAQ-GS

IDEXX Laboratories, Inc.

Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances

Reference price$569.54As of Jul 28, 2026
Market capitalization$44.93B
52-week range$518.55–$769.98
S&P 500 portfolio weight0.07%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$620.00+8.9% vs. reference
Average$710.40+24.7% vs. reference
High$805.00+41.3% vs. reference
4 Buy2 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 4, 2026Jun 2026
Consensus EPS$3.956 estimates
Expected range$3.81–$4.03Low to high EPS
Dec 2026$14.68Street EPS consensus
Dec 2027$16.53Street EPS consensus
Dec 2028$18.70Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue+10.4% YoY$4.3B$3.9B
Operating income$1.36B$1.13B
Net income$1.06B$0.89B
Operating cash flow$1.18B$0.93B
Capital expenditures($0.12B)($0.12B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Here's How IDEXX Laboratories Is Placed Ahead of Q2 Earnings

Zacks

Can ISRG Maintain Its Premium Valuation Amid Slower Procedure Growth?

BNK Invest

MSCI Takes Over #243 Spot From Idexx Laboratories

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.